Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

N. Peacock · SciRah

Researcher profile · Semantic Scholar

N. Peacock

Share profile

N. Peacock — researcher profile on SciRah

h-index: 15
Works: 60
Citations: 1,191

Most-cited papers

Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab.
D. Spigel, J. Hainsworth, D. Yardley, E. Raefsky +5 more
2010Journal of Clinical Oncology298 citations
Semantic Scholar
Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study.
J. Gilmore, N. Peacock, A. Gu, Stephen Szabo +8 more
2014Journal of Oncology Practice173 citations
Semantic Scholar
Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer.
A. Storniolo, M. Pegram, B. Overmoyer, P. Silverman +11 more
2008Journal of Clinical Oncology125 citations Open access
Semantic Scholar
A phase II trial of ixabepilone and cyclophosphamide as neoadjuvant therapy for patients with HER2-negative breast cancer: correlation of pathologic complete response with the 21-gene recurrence score
D. Yardley, N. Peacock, M. Shastry, Howard A. Iii Burris +5 more
2015Breast Cancer Research and Treatment54 citations
Semantic Scholar
Patient perspectives on breast cancer treatment plan and summary documents in community oncology care
V. Blinder, Virginia W. Norris, N. Peacock, Jennifer J. Griggs +4 more
2013Cancer54 citations
Semantic Scholar
Phase 1 Results From a Study of Romidepsin in Combination With Gemcitabine in Patients With Advanced Solid Tumors
S. Jones, J. Infante, D. Spigel, N. Peacock +4 more
2012Cancer Investigation47 citations
Semantic Scholar
A Phase II Trial of DaunoXome, Liposome‐ Encapsulated Daunorubicin, in Patients with Metastatic Adenocarcinoma of the Colon
J. Eckardt, E. Campbell, H. Bums, Geoffrey R. Weiss +8 more
1994American Journal of Clinical Oncology39 citations
Semantic Scholar
Taste preferences for oral nutrition supplements in patients before and after pelvic radiotherapy: a double-blind controlled study.
C. McGough, N. Peacock, C. Hackett, C. Baldwin +8 more
2006Clinical Nutrition30 citations
Semantic Scholar
A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer
D. Yardley, H. Burris, N. Peacock, E. Raefsky +4 more
2010Breast Cancer Research and Treatment27 citations
Semantic Scholar
The lupus anticoagulant-hypoprothrombinemia syndrome
N. Peacock, S. P. Levine
199427 citations
Semantic Scholar
Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute
D. Yardley, Linda D. Bosserman, J. O'Shaughnessy, W. Harwin +6 more
2015Breast Cancer Research and Treatment26 citations
Semantic Scholar
A phase I study of the dual kinase inhibitor GW572016 in combination with paclitaxel (EGF10009).
S. Jones, J. Hainsworth, D. Spigel, N. Peacock +6 more
2004Journal of Clinical Oncology23 citations
Semantic Scholar
Rituximab, Lenalidomide, and Bortezomib in the First-Line or Second-Line Treatment of Patients with Mantle Cell Lymphoma a Phase I/II Trial.
I. Flinn, M. Mainwaring, N. Peacock, D. Shipley +4 more
201219 citations
Semantic Scholar
A phase I study of docetaxel and 5-fluorouracil in patients with advanced solid malignancies.
T. Petit, C. Aylesworth, H. Burris, P. Ravdin +7 more
1999Annals of Oncology17 citations Open access
Semantic Scholar
A Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Octreotide LAR for Patients with Advanced Neuroendocrine Cancers
J. Bendell, A. Zakari, E. Lang, D. Waterhouse +8 more
2016Cancer Investigation16 citations
Semantic Scholar
Case Report: The Lupus Anticoagulant‐Hypoprothrombinemia Syndrome
N. Peacock, S. P. Levine
1994American Journal of the Medical Sciences15 citations
Semantic Scholar
Phase I/II trial of neoadjuvant sunitinib administered with weekly paclitaxel/carboplatin in patients with locally advanced triple-negative breast cancer
D. Yardley, D. Shipley, N. Peacock, M. Shastry +3 more
2015Breast Cancer Research and Treatment14 citations
Semantic Scholar
Preliminary results of a multicenter phase II trial of vinflunine (with trastuzumab in HER2+ pts) as first-line treatment in metastatic breast cancer
N. Peacock, D. Spigel, M. Mainwaring, Dana Statton Thompson +6 more
200714 citations
Semantic Scholar
Docetaxel (Taxotere) in combination: a step forward.
H. Burris, S. Fields, N. Peacock
1995Seminars in Oncology14 citations
Semantic Scholar
A phase II feasibility trial of dose-dense docetaxel followed by doxorubicin/cyclophosphamide as adjuvant or neoadjuvant treatment for women with node-positive or high-risk node-negative breast cancer.
D. Yardley, H. Burris, C. Farley, J. Barton +4 more
2008Clinical Breast Cancer13 citations
Semantic Scholar
Bevacizumab, pertuzumab, and sandostatin for patients (pts) with advanced neuroendocrine cancers (NET).
Irfan Firdaus, K. Shih, A. Zakari, E. Lang +7 more
201212 citations
Semantic Scholar
A pilot study of adjuvant doxorubicin and cyclophosphamide followed by paclitaxel and sorafenib in women with node-positive or high-risk early-stage breast cancer.
D. Spigel, J. Hainsworth, H. Burris, D. Molthrop +5 more
2011Clinical advances in hematology & oncology : H&O12 citations
Semantic Scholar
A phase I study of panobinostat (LBH589) with capecitabine with or without lapatinib.
N. Peacock, S. Jones, D. Yardley, J. Bendell +3 more
201012 citations
Semantic Scholar
A phase II trial of neoadjuvant gemcitabine, epirubicin, and docetaxel as primary treatment of patients with locally advanced or inflammatory breast cancer.
D. Yardley, N. Peacock, N. Dickson, M. White +6 more
2010Clinical Breast Cancer12 citations
Semantic Scholar
A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC).
D. Yardley, R. Young, K. Adelson, A. Silber +8 more
2021Clinical Breast Cancer9 citations
Semantic Scholar
Everolimus with paclitaxel plus bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (MBC): A randomized, double-blind, placebo-controlled phase II trial of the Sarah Cannon Research Institute (SCRI).
D. Yardley, Linda D. Bosserman, N. Peacock, A. Favret +7 more
20128 citations
Semantic Scholar
Efficacy results from a multicenter phase II noncomparative two-arm pilot trial of bevacizumab with anastrozole or fulvestrant as first-line endocrine therapy for metastatic breast cancer.
M. Rubin, J. Barton, D. Shipley, E. Arrowsmith +6 more
2016Journal of Clinical Oncology6 citations
Semantic Scholar
A phase I/II study of CR011-vcMMAE, an antibody-drug conjugate, in patients (pts) with locally advanced or metastatic breast cancer (MBC).
N. Peacock, M. Saleh, J. Bendell, April A. N. Rose +5 more
2016Journal of Clinical Oncology6 citations Open access
Semantic Scholar
P5-13-09: Correlation of Oncotype DX Recurrence Scores with Pathologic Response Following Neoadjuvant Ixabepilone and Cyclophosphamide in Patients with HER2−Negative Breast Cancer: A Sarah Cannon Research Institute Phase II Trial.
D. Yardley, N. Peacock, C. Hendricks, S. Huh +5 more
20116 citations
Semantic Scholar
Phase II trial of gemcitabine plus trastuzumab in minimally pretreated HER2 overexpressing metastatic breast cancer
N. Peacock, J. Bearden, F. Schnell, M. White +6 more
20056 citations
Semantic Scholar
Phase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapy
D. Yardley, N. Peacock, B. Daniel, Betrand Anz +9 more
2020Breast Cancer Research and Treatment5 citations
Semantic Scholar
Abstract P5-14-04: A phase 2 study evaluating orteronel, an inhibitor of androgen biosynthesis, in patients with androgen receptor (AR)-expressing metastatic breast cancer: Interim analysis
D. Yardley, N. Peacock, R. Young, A. Silber +8 more
20165 citations
Semantic Scholar
A phase II trial of biweekly pemetrexed (P) and gemcitabine (G) in the first-line treatment (tx) of patients (pts) with advanced non-small cell lung cancer (NSCLC).
N. Peacock, D. Spigel, J. Hainsworth, D. Yardley +6 more
2006Journal of Clinical Oncology5 citations
Semantic Scholar
Preliminary safety results from a multicenter phase II noncomparative two arm pilot of bevacizumab with anastrozole or fulvestrant as 1stline metastatic breast cancer therapy.
D. Yardley, N. Peacock, E. Arrowsmith, W. Harwin +6 more
20094 citations
Semantic Scholar
A phase I trial of vinorelbine in combination with mitoxantrone in patients with refractory solid tumors
N. Peacock, H. Burris, V. Diéras, L. Smith +7 more
2004Investigational new drugs4 citations
Semantic Scholar
Real-world (RW) risk of recurrence among patients (pts) diagnosed with stage II-III HR+/HER2− early breast cancer (EBC) treated with endocrine therapy (ET) in the US.
P. Razavi, Mehnaj S. Ahmed, Ashley Roush, Rohan C. Parikh +13 more
2024Journal of Clinical Oncology3 citations
Semantic Scholar
Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting (CINV) in U.S. community oncology practice: INSPIRE study.
J. Gilmore, N. Peacock, A. Gu, Stephen Szabo +8 more
2012Journal of Clinical Oncology3 citations
Semantic Scholar
Ixabepilone and cyclophosphamide as neoadjuvant therapy in HER2-negative breast cancer with exploratory Oncotype DX assessments: A Sarah Cannon Research Institute phase II trial.
N. Peacock, D. Yardley, C. Hendricks, S. Huh +7 more
2011Journal of Clinical Oncology3 citations
Semantic Scholar
Biweekly neoadjuvant gemcitabine, epirubicin, and nano-particle albumin bound (nab) paclitaxel (GEA) with tumor SPARC analysis correlated with pathologic responses: Results of a multicenter phase II trial
B. Daniel, H. Doss, V. Gian, A. Meluch +6 more
20073 citations
Semantic Scholar
Phase II trial of gemcitabine and carboplatin, plus trastuzumab in HER2+ patients as first line therapy in metastatic breast cancer.
D. Yardley, N. Peacock, D. Shipley, D. Waterhouse +6 more
2006Journal of Clinical Oncology3 citations
Semantic Scholar
Day 1 pegfilgrastim with dose dense adjuvant chemotherapy: Amelioration of docetaxel neutropenia but not that of doxorubicin/cyclophosphamide. Results from a Sarah Cannon Research Institute pilot study
D. Yardley, F. Greco, H. Burris, N. Peacock +6 more
20053 citations
Semantic Scholar
Abstract PS11-29: A phase 2 study evaluating orteronel, an inhibitor of androgen biosynthesis, in patients with androgen receptor (AR)-expressing metastatic triple-negative breast cancer (TNBC)
D. Yardley, R. Young, K. Adelson, A. Silber +7 more
20212 citations
Semantic Scholar
Preliminary safety results from a multicenter phase II trial of nanoparticle albumin-bound paclitaxel/cyclophosphamide in early stage breast cancer plus trastuzumab in HER-2+ patients (pts).
E. Raefsky, R. Inhorn, M. Lange, N. Peacock +6 more
2016Journal of Clinical Oncology2 citations
Semantic Scholar
Patient perspectives on a treatment plan and summary program in community oncology care.
V. Blinder, Virginia W. Norris, N. Peacock, Jennifer J. Griggs +4 more
2011Journal of Clinical Oncology2 citations
Semantic Scholar
P3-14-29: Neoadjuvant Sunitinib Administered with Weekly Paclitaxel/Carboplatin in Patients with Locally Advanced Triple-Negative Breast Cancer: A Sarah Cannon Research Institute Phase I/II Trial.
D. Yardley, N. Peacock, J. Peyton, D. Shipley +7 more
20112 citations
Semantic Scholar
Abstract P5-06-06: The Safety and Tolerability of Panobinostat (LBH589) in Combination with Capecitabine +/− Lapatinib: A Phase I Study in HER2+ Breast Cancer
N. Peacock, S. Jones, D. Yardley, J. Bendell +3 more
20102 citations
Semantic Scholar
Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients (pts) with HER2-positive metastatic breast cancer (MBC)
N. Peacock, J. Infante, D. Yardley, H. Burris +5 more
20082 citations
Semantic Scholar
Abstract P1-12-04: A phase 2 study of eribulin in breast cancer not achieving a pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC)
D. Yardley, N. Peacock, S. Shroff, D. Molthrop +12 more
20161 citations
Semantic Scholar
Abstract OT2-1-07: A phase II study with orteronel as monotherapy in patients with androgen receptor (AR) expressing metastatic breast cancer (MBC)
D. Yardley, S. Jones, N. Peacock, M. Shastry +3 more
20151 citations
Semantic Scholar
Abstract 2397: Correlation between biomarker status and response to EGFR inhibition in triple-negative breast cancer (TNBC): findings from a Phase II trial.
D. Yardley, Zeqiang Ma, P. Ward, C. Hendricks +6 more
20131 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

J. Hainsworth×25
Invite
J. Hainsworth — researcher profile on SciRah
D. Yardley×18
Invite
D. Yardley — researcher profile on SciRah
H. Burris×18
Invite
H. Burris — researcher profile on SciRah
D. Yardley×13
Invite
D. Yardley — researcher profile on SciRah

×11

Invite

D. Spigel — researcher profile on SciRah

Invite

M. Shastry — researcher profile on SciRah

Invite

D. Shipley — researcher profile on SciRah

Invite

F. Greco — researcher profile on SciRah

Invite

S. Jones — researcher profile on SciRah

Invite

J. Barton — researcher profile on SciRah

Invite

R. Young — researcher profile on SciRah

Invite

W. Harwin — researcher profile on SciRah